References
- Marty, M (ed). Manual of GM-CSF. Oxford, UK Blackwell Sciences; 1996.
- Lau AS, Lehmann D, Geertsma FR, Yeung MC. Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons. Pediatr Infect Dis J 1996;15:563–575.
- Furman WL, Grist WM. Potential uses of recombinant human granulocyte—macrophage colony stim-ulating factor in children. AmJ Pediatr Hematol Oncol. 1991;13:388–399.
- Furman WL, Fairclough DL, Huhn RD, et al. Therapeutic effects and pharmacokinetics of recom-binant granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 1991;9:1022–1028.
- Furman WL, Fairclough DL, Cain AM, Arnold BA, Meyer WH, Grist WM. Use of GM-CSF in children after high-dose chemotherapy. Med Pediatr Oncol Suppl. 1992;2:26–30.
- Riiko nen P, Saarinen UM, Makipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 1994;13:197–202.
- Schrezenmeier H, Raghavachar A, Heimpel H. Granulocyte-macrophage colony-stimulating factor in the sera of patients with aplastic anemia. Clin InvesL 1993;71:102–108.
- Stute N, Santana VM, Rodman JH, Scheel MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992;79:2849–2854.
- Stute N, Furman WL, Schell M, Evans WE. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administra-tion. J Pharm Sci. 1995;84:824–828.
- Ragnhammar P, Friesen HJ, Fri5din JE, et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coh-derived) antibodies and clinical effects in non-immunocompromised patients. Blood. 1994;84:4078–4087.
- Schmidt W, Maass G, Buschle M, et al. Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferinfection (AVET). Gene. 1997;190:211–216.
- Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccina-tion with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther. 1997;8:1065–1072.
- Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with super-antigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest. 1998;101:2406–2414.
- Heil G, Chadid L, Hoelzer D. GM-CSF in the therapy of de-novo AML patients: an update of a double-blind randomized, placebo controlled trial. Ann Hematol. 1995;70 (Suppl. 2) A133.
- Takahashi M, Nikkuni K, Moriyama A, Shibata A. GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase and cholesterol. AmJ Hematol. 1991;36:213–214.